Cargando…

Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project

The Chimeric Antigen Receptor (CAR) T Cell Safety Database Project explored the use of cross-study safety data to identify risk factors associated with severe cytokine release syndrome (sCRS) and severe neurological toxicities (sNTX) after CAR T cell administration. Sponsors voluntarily submitted da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foster, Matthew, Negash, Yonatan, Eberhardt, Leslie, Bryan, Wilson W., Schultz, Kimberly, Wang, Xiaofei, Xu, Yuan, George, Bindu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643340/ https://www.ncbi.nlm.nih.gov/pubmed/36381656 http://dx.doi.org/10.1016/j.omto.2022.10.006

Ejemplares similares

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

CAR-T Cells and the Kidney: Insights from the WHO Safety Database
por: Gérard, Alexandre O., et al.
Publicado: (2023)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

FDA MAUDE database analysis of titanium middle ear prosthesis
por: Carey, Jaclyn, et al.
Publicado: (2022)

Microdebrider complications in sinus surgery: Analysis of the openFDA database
por: Saba, Elias S., et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project
por: de Bie, Sandra, et al.
Publicado: (2015)

Understanding Vaccine Safety and the Roles of the FDA and the CDC
por: Meissner, H. Cody
Publicado: (2022)

The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
por: Major, Jacqueline M., et al.
Publicado: (2018)

In silico toxicology models and databases as FDA Critical Path Initiative toolkits
por: Valerio, Luis G
Publicado: (2011)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database
por: Fordyce, Christopher B., et al.
Publicado: (2019)

Pilot project "Patient-Safety" in Medical Education
por: Rosentreter, Michael, et al.
Publicado: (2011)

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database
por: Liguori, Valerio, et al.
Publicado: (2023)

Overhauling CAR T Cells to Improve Efficacy, Safety and Cost
por: Chicaybam, Leonardo, et al.
Publicado: (2020)

Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database
por: Tian, Xiaojiang, et al.
Publicado: (2021)

Safety reporting of Essure medical device: a qualitative and quantitative assessment on the FDA manufacturer and user facility device experience database in 2018
por: Zou, Chenyu, et al.
Publicado: (2023)

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015)

Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot
por: Gao, Ya Grace, et al.
Publicado: (2022)

FDA oversight of medical devices
por: Hill, Matthew W, et al.
Publicado: (2012)

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
por: Lehrer, Steven, et al.
Publicado: (2018)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Death by Implants: Critical Analysis of the FDA-MAUDE Database on Breast Implant-related Mortality
por: Abi-Rafeh, Jad, et al.
Publicado: (2019)

The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database
por: Benjamens, Stan, et al.
Publicado: (2020)

Robotic stapler use: Is it safe?–FDA database analysis across multiple surgical specialties
por: Giffen, Zane, et al.
Publicado: (2021)

ProCarDB: a database of bacterial carotenoids
por: Nupur, L. N. U., et al.
Publicado: (2016)

OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
por: Kass-Hout, Taha A, et al.
Publicado: (2016)

Towards an FDA-cleared basophil activation test
por: Alpan, Oral, et al.
Publicado: (2023)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Analysis of reported adverse events of pipeline stents for intracranial aneurysms using the FDA MAUDE database
por: Porwal, Mokshal H., et al.
Publicado: (2023)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
por: Kramer, Judith M., et al.
Publicado: (2014)

Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database
por: Zhu, Jianhong, et al.
Publicado: (2021)

Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project
por: Bramanti, Stefania, et al.
Publicado: (2022)

VARC consensus report: the FDA perspective(†)
por: Hillebrenner, Matthew G., et al.
Publicado: (2011)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
por: Murphy, Ravindhi, et al.
Publicado: (2023)

Rapid Development of the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Pilot Project to Monitor Adverse Events Reported in Association with COVID-19 Therapeutics
por: Wax, P.M., et al.
Publicado: (2021)

The FDA Changed Everything
por: Geantă, Marius, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ckphhn8gq1vqs9l92akv9mtbva